Clinical trials: Breast Tumor Tissue
Antineoplastic Combined Chemotherapy Protocols
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
The regimen PLD plus cyclophosphamide 4 cycles followed by paclitaxel or docetaxel 4 cycles(noted in phase II CAPRICE) will be used as experimental group.
- Trial name
- NCT02953184
- Testing
- Pegylated Liposomal Doxorubicin, Cyclophosphamide, Taxotere
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Jilin University
Breast Cancer
Timing of Specific Exercise Therapy After Breast Cancer Surgery: Early Versus Delayed Initiation
This single-center, parallel-group randomized controlled trial (RCT) will compare two timings for initiating specific exercise therapy after breast cancer surgery.
- Trial name
- BEST-Timing (NCT06918184)
- Testing
- Specific Exercise Therapy
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Al Hayah University In Cairo
Intraductal Carcinoma and Lobular Carcinoma in Situ
Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast
When invasive components are discovered at mastectomy for vacuum-assisted biopsy (VAB)-diagnosed ductal carcinoma in situ (DCIS), the only option available is axillary lymph node dissection (ALND).
- Trial name
- CINNAMOME (NCT01841749)
- Testing
- sentinel node biopsy and mastectomy
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Institut Bergonié
Breast Cancer, Mastectomy; Lymphedema
OPERA - Incorporating Robotic Surgery in Both Mastectomy and DIEP Flap Reconstruction
Current breast cancer surgery is achieving minimally invasive approach to reduce incision while providing better surgical vision and freedom in mastectomy.
- Trial name
- NCT06415526
- Testing
- OPERA
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- Chang Gung Memorial Hospital
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer.
- Conditions
- Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer
- Trial name
- CAPELA (NCT07222215)
- Testing
- Capecitabine, Elacestrant
- Where
- United States
- Volunteers
- 297 people
- Sponsor
- Kristina A. Fanucci
Breast Cancer
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus bevacizumab as first line treatment in patients with metastatic and HER2 negative breast cancer.
- Trial name
- NCT00705315
- Testing
- Docetaxel, Epirubicin, Bevacizumab
- Where
- 10 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
HER2 + Breast Cancer
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Patients with Stage II-III HER2-positive breast cancer will receive three cycles of treatment with Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab, followed by imaging assessment.
- Trial name
- NCT07393425
- Testing
- Trastuzumab Deruxtecan, Pertuzumab, Taxane Chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer
Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer
Breast cancer is the first cancer in women and 60% of new cases occurring in women 50 to 74 years old. With about 50,000 new cases, it is the second cancer the most serious cancers.
- Trial name
- HORMONOVILLE (NCT04142476)
- Testing
- interview
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Centre Georges Francois Leclerc
Breast Neoplasms
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
Based on different HR status, we explored the efficacy and safety of Pyrotinib and Dalpiciclib Isethionate Tablets based combination regimen in the first-line treatment of HER2 + MBC.
- Trial name
- NCT05328440
- Testing
- Pyrotinib Maleate, Dalpiciclib Isethionate Tablets, Inetetamab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Breast Surgery
Hemodynamic Effects of Intradermal Methylene Blue During Breast Surgery Under General Anesthesia
This prospective observational study aims to evaluate the effects of intradermal methylene blue injection on intraoperative hemodynamic stability in patients undergoing breast surgery under general anesthesia.
- Conditions
- Breast Cancer, Breast Surgery, Sentinel Lymph Node Biopsy, Methylene Blue
- Trial name
- NCT07040540
- Testing
- Methylene Blue, Standard Surgical Care Without Dye
- Where
- Turkey (Türkiye)
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Breast Cancer
Retrospective and Prospective Evaluation of Scapulohumeral Comfort, Aesthetic Result and Quality of Life
The dorsalis major flap is an interesting therapeutic option in breast reconstruction because of reliability and reproducibility.
- Trial name
- QUARLAMI (NCT05316389)
- Testing
- Breast reconstruction
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer
Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study
In 2005, the EBCIG demonstrated the efficacy of tamoxifen in improving overall survival in hormone receptor positive breast cancers.
- Trial name
- AIMS (NCT00653718)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Breast Cancer
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
The purpose of this study is to microscopically examine breast cancer cells of pre-menopausal and post-menopausal women before and after exposure to one of the two commonly used breast cancer drugs, tamoxifen or fulvestrant.
- Trial name
- NCT02936206
- Testing
- Fulvestrant, Tamoxifen
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
The primary objective of this study is to investigate the efficacy and safety of a fasting-mimicking diet (FMD) intervention combined with standard neoadjuvant chemoimmunotherapy in early-stage or locally advanced triple-negative…
- Trial name
- FACT-TN (NCT07378306)
- Testing
- Fasting-mimicking diet, Chemotherapy, Toripalimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Anemia, Breast Neoplasms
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
The purpose of this study is to evaluate the impact on survival and quality of life of maintaining hemoglobin in the range of 12 to 14 g/dL using epoetin alfa or placebo in patients starting chemotherapy for metastatic breast…
- Conditions
- Anemia, Breast Neoplasms, Quality of Life
- Trial name
- NCT00211133
- Testing
- epoetin alfa
- Volunteers
- 939 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Breast/Surgery
Nipple-sparing Mastectomy in Combined With Buried Flap Monitoring
1. Learning curve of ms-Tram and DIEP breast reconstructions surgery are important to guide the training of new surgeon. 2. Buried flap post operative monitoring without implantable doppler was seldom studied, a validated…
- Trial name
- NCT05560633
- Testing
- No intervention
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
TNBC, Triple Negative Breast Cancer, Brain Metastasases
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
This is an open-label, prospective, two-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with…
- Trial name
- ABC-R (NCT07638852)
- Testing
- Radiation Therapy, Adebelimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Breast Cancer
Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.
- Trial name
- NCT03983538
- Testing
- Mathematical modeling to predict response to chemotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New Mexico Cancer Research Alliance
Breast Cancer
Exploratory Study Comparing ClearSight System 2D Map to Post Surgery Histopathological Analysis in Lumpectomy
Prospective, single-arm, multicenter, open label, non-randomized exploratory clinical study comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
- Trial name
- NCT02679378
- Testing
- ClearSight™ System
- Where
- 5 sites in United States, Israel
- Volunteers
- 220 people
- Sponsor
- Clear Cut Medical Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.